New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 8, 2013
13:26 EDTKPTIKaryopharm announces data supporting potential of Selinexor
Karyopharm Therapeutics announced preclinical and clinical data supporting the potential of its lead oral SINE compound Selinexor, KPT-330, in patients with relapsed and/or refractory acute myeloid leukemia, AML, multiple myeloma, MM, and other hematologic malignancies presented as posters at the 2013 American Society of Hematology, ASH, Annual Meeting being held in New Orleans. Selinexor inhibits Exportin 1 [XPO1, also called CRM1], preventing the exportation of tumor suppressor proteins from, and leading to their accumulation in, the nucleus, which reinitiates and amplifies their natural apoptotic function in cancer cells. Selinexor is being evaluated in both hematologic malignancies and solid tumors with registration directed trials expected to commence in two indications in the first half of 2014.
News For KPTI From The Last 14 Days
Check below for free stories on KPTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
16:08 EDTKPTIKaryopharm announces initiation of Phase 1 study of Selinexor-decitabine combo
Karyopharm Therapeutics announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor in combination with the DNA methylation inhibitor decitabine in patients with relapsed or refractory acute myeloid leukemia, or AML, and in patients age 60 years with newly diagnosed AML. Sharon Shacham, Karyopharm's founder, President and Chief Scientific Officer, commented, "This first combination study of Selinexor represents a significant milestone for the company as we look to broaden the scope of SINE compounds in the treatment of cancers."
April 9, 2014
10:02 EDTKPTIKaryopharm enters into preferred provider agreement with Clinipace Worldwide
Clinipace Worldwide announced that Karyopharm Therapeutics has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology, wound healing, and other diseases. As part of a long-term strategic partnership, Clinipace expects to manage numerous study starts on behalf of Karyopharm in 2014.
April 7, 2014
17:11 EDTKPTIKaryopharm requests withdrawal of registration statement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use